Results 201 to 210 of about 28,282,310 (344)

Discovery of H2 Receptor Antagonists as Colistin Enhancers by Targeting Acid Stress Response

Advanced Science, EarlyView.
This study identifies YqgB as a key target for restoring colistin susceptibility in mcr‐positive pathogens under acidic conditions by remodeling phospholipid composition and reducing LPS modification. Deep learning‐based screening reveals H2 receptor antagonists as novel colistin adjuvants. Further investigations indicate that ranitidine and famotidine
Jinju Cai, Mengping He, Jianya Luo, Shuang Zhou, Tengyue Zhang, Jianing Li, Zhiqiang Wang, Yuan Liu   +7 more
wiley   +1 more source

Targeting interleukin-1 signaling for renoprotection. [PDF]

Front Immunol
Bogdanova D, Samsonov MY, Lebedeva S, Bukhanova D, Materenchuk M, Mutig K.   +5 more
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Evaluation of salivary interleukin 6 interleukin 1 beta and interferon gamma in oral and mucocutaneous lichen planus patients. [PDF]

Sci Rep
Hama PN, Ahmed KM.
europepmc   +1 more source

BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer‐Associated Fibroblasts Crosstalk

Advanced Science, EarlyView.
This study reveals that m6A regulators cooperatively upregulate BGN in melanoma, promoting malignancy. Within the tumor microenvironment, CAFs show highest BGN expression. The BGN/MDK axis mediates cancer‐stroma crosstalk, driving normal fibroblast (NF) activation and enhancing the pro‐tumor effect of CAFs, highlighting a promising therapeutic target ...
Hao‐ze Shi, Ming‐yang Wu, Jin‐quan Liu, Cuicui Tian, Li Ma, Xue‐mei Zhou, Ze‐Hao Sun, Zhi‐yong Xu, Run‐dong Zhang, Shan‐yuan Ye, Li‐ming Huang, Yan Wang, Jing‐shu Xiong, Wen‐bo Bu, Xian‐feng Cheng, Jian‐fang Sun, Hao Chen   +16 more
wiley   +1 more source

Cleaved SREBP-2 C-terminal fragment noncanonically drives interleukin-1 receptor-associated kinase 1-dependent apoptosis. [PDF]

Signal Transduct Target Ther
Yeon M, Kim WK, Shin HB, Lee YB, Rhee HW, Seo YK.   +5 more
europepmc   +1 more source

Endogenous “Time Bomb” – Mislocalized Phospholipase A2 as a Critical Mediator of Ultra‐Rapid Mortality in Sepsis and Acute Lung Injury

Advanced Science, EarlyView.
Phospholipase A2 (PLA2), a dormant enzyme, becomes lethal when activated—collapsing lungs in minutes. Our dual therapy (DOPS + varespladib) boosts survival from 0% to >90% in sepsis/ALI. A breakthrough for acute lung injury treatment. ABSTRACT This study reveals that phospholipase A2 (PLA2), normally stable and nontoxic, can be activated specifically ...
Jianyu Wang, Zhongxing Xu, Lin Wang, Xin Sui, Yuan Luo, Xiuli Zhao, Jun Yang, Yongan Wang   +7 more
wiley   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Interleukin-1 and Cancer

Chinese Journal of Lung Cancer, 2010
Xiang WU, Ke XU
doaj  

Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist. [PDF]

JAAD Case Rep
Mooney N, Grewal A, Pei S, Bogner P, Kuraitis D.   +4 more
europepmc   +1 more source